Propanc Biopharma plans Phase 1b trial for cancer drug PRP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Propanc Biopharma plans Phase 1b trial for cancer drug PRP

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

August 12, 2026 8:30 AM EDT

Contrasting Science with Revolution Medicines and Erasca

MELBOURNE, Australia, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (Propanc or the Company), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today provided a scientific comparison of its lead candidate PRP with the RAS-targeted approaches of Revolution Medicines, Inc. and Erasca, Inc. The Company articulates why PRPs unique mechanismpromoting cancer cell differentiation, reversing epithelial-mesenchymal transition (EMT), and targeting cancer stem cells via pancreatic proenzymespositions it as a potential long-term therapy of choice, particularly for aggressive,... More